TrxR1 Cancer Research Results

TrxR1, thioredoxin reductase 1: Click to Expand ⟱
Source:
Type:
TrxR1 or TXNRD1 (Thioredoxin Reductase 1)
Redox Control, Stress Tolerance, and Therapy Resistance
• Many studies have found that an elevated expression of TrxR1 in breast tumors, NSCLC, HCC correlates with increased tumor aggressiveness and a poorer prognosis.
-TrxR1 expression was elevated by >50 fold in FaDu and HeLa cells, and by >20 fold in SCC-1 compared to either MSK-Leuk1 or keratinocytes.

High TXNRD1 expression often associates with:
-Advanced stage
-Therapy resistance
-Reduced survival

TrxR1 Inhibition
-Collapses redox control
-Causes rapid ROS accumulation
-Triggers apoptosis, especially in high-stress tumors


Scientific Papers found: Click to Expand⟱
5862- carbop,  Cisplatin,    Molecular Mechanisms of Resistance and Toxicity Associated with Platinating Agents
- Review, Var, NA
DNAdam↑, ER Stress↑, UPR↑, ATF4↑, ATF6↑, XBP-1↑, GRP78/BiP↑, NP/CIPN↝, toxicity↝, eff↑, TrxR1⇅,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

TrxR1⇅, 1,  

Protein Folding & ER Stress

ATF6↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,   UPR↑, 1,   XBP-1↑, 1,  

DNA Damage & Repair

DNAdam↑, 1,  

Angiogenesis & Vasculature

ATF4↑, 1,  

Drug Metabolism & Resistance

eff↑, 1,  

Functional Outcomes

NP/CIPN↝, 1,   toxicity↝, 1,  
Total Targets: 11

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TrxR1, thioredoxin reductase 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1207  State#:%  Dir#:3
wNotes=0 sortOrder:rid,rpid

 

Home Page